Blocking oncogenic Ras signaling for cancer therapy.

作者: A. A. Adjei

DOI: 10.1093/JNCI/93.14.1062

关键词:

摘要: The Ras gene product is a monomeric membrane-localized G protein of 21 kd that functions as molecular switch linking receptor and nonreceptor tyrosine kinase activation to downstream cytoplasmic or nuclear events. Each mammalian cell contains at least three distinct ras proto-oncogenes encoding closely related, but proteins. Activating mutations in these proteins result constitutive signaling, thereby stimulating proliferation inhibiting apoptosis. Oncogenic the are present approximately 30% all human cancers. K-ras occur frequently non-small-cell lung, colorectal, pancreatic carcinomas; H-ras common bladder, kidney, thyroid N-ras found melanoma, hepatocellular carcinoma, hematologic malignancies. ras-signaling pathway has attracted considerable attention target for anticancer therapy because its important role carcinogenesis. In this review, physiologic biochemical properties proteins, their mechanism relation cancer will be discussed. Novel therapeutic approaches based on inhibition Ras-mediated including processing, synthesis, blockage effectors,

参考文章(154)
S G Kennedy, A J Wagner, S D Conzen, J Jordan, A Bellacosa, P N Tsichlis, N Hay, The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes & Development. ,vol. 11, pp. 701- 713 ,(1997) , 10.1101/GAD.11.6.701
T I Bonner, S B Kerby, P Sutrave, M A Gunnell, G Mark, U R Rapp, Structure and biological activity of human homologs of the raf/mil oncogene. Molecular and Cellular Biology. ,vol. 5, pp. 1400- 1407 ,(1985) , 10.1128/MCB.5.6.1400
Asim Khwaja, Pablo Rodriguez‐Viciana, Stefan Wennström, Patricia H Warne, Julian Downward, Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway The EMBO Journal. ,vol. 16, pp. 2783- 2793 ,(1997) , 10.1093/EMBOJ/16.10.2783
Jalila Adnane, Francisco A. Bizouarn, Yimin Qian, Andrew D. Hamilton, Saïd M. Sebti, p21WAF1/CIP1 Is Upregulated by the Geranylgeranyltransferase I Inhibitor GGTI-298 through a Transforming Growth Factor β- and Sp1-Responsive Element: Involvement of the Small GTPase RhoA Molecular and Cellular Biology. ,vol. 18, pp. 6962- 6970 ,(1998) , 10.1128/MCB.18.12.6962
R J Muschel, V J Bakanauskas, C C Ling, B Endlich, M C Weiss, W G McKenna, M L Kelsten, Synergistic Effect of the v-myc Oncogene with H-ras on Radioresistance Cancer Research. ,vol. 50, pp. 97- 102 ,(1990)
Rodney J. Landreneau, Phouthone Keohavong, Mary Ann A DeMichele, Alea C. Melacrinos, Robert J. Weyant, Jill M. Siegfried, Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clinical Cancer Research. ,vol. 2, pp. 411- 418 ,(1996)
M Morrin, M Kelly, N Barrett, P Delaney, Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut. ,vol. 35, pp. 1627- 1631 ,(1994) , 10.1136/GUT.35.11.1627
Raymond J. Hohl, Nicholas Patronas, David J. Venzon, Jane Trepel, Alain Thibault, Anne C. Tompkins, Eddie Reed, William D. Figg, Bertrand Liang, Charles E Myers, Charles E Myers, Dvorit Samid, Dvorit Samid, Michael R. Cooper, Michael R. Cooper, Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clinical Cancer Research. ,vol. 2, pp. 483- 491 ,(1996)
D Stokoe, S. Macdonald, K Cadwallader, M Symons, J. Hancock, Activation of Raf as a result of recruitment to the plasma membrane Science. ,vol. 264, pp. 1463- 1467 ,(1994) , 10.1126/SCIENCE.7811320
Michael Karin, The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases Journal of Biological Chemistry. ,vol. 270, pp. 16483- 16486 ,(1995) , 10.1074/JBC.270.28.16483